POLY(RI):POLY(RC) (HIGH MW)
Glioblastoma
Beijing Tiantan Hospitalnucleic_acidPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 65/ 100
Competitive context
234 Active assets in the Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE University of Cincinnati | Phase 3 | BB |
Enzastaurin Denovo Biopharma LLC | Phase 3 | BB |
Inno-206 Université de Sherbrooke | Phase 2 | BB |
ETOPOSIDE Sichuan Honghe Biotechnology Co., Ltd. | Phase 2/3 | BB |
Paxalisib Institute of Cancer Research, United Kingdom | Phase 2/3 | B |
View all 50 →
Same molecule, other indications
POLY(RI):POLY(RC) (HIGH MW) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →